<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00752401</url>
  </required_header>
  <id_info>
    <org_study_id>VitaD-1</org_study_id>
    <secondary_id>EudraCT Number 2008-002807-21</secondary_id>
    <nct_id>NCT00752401</nct_id>
  </id_info>
  <brief_title>Vitamin D3 Substitution in Vitamin D Deficient Kidney Transplant Recipients</brief_title>
  <acronym>VITA-D</acronym>
  <official_title>VITA-D: Cholecalciferol Substitution in Vitamin D Deficient Kidney Transplant Recipients: A Randomized, Placebo-controlled Study to Evaluate the Posttransplant Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the effects of Cholecalciferol (Vitamin D3)&#xD;
      substitution on the posttransplant outcome (glomerular filtration rate as well as serum&#xD;
      creatinine levels, number of acute rejection episodes, number of infections and C-reactive&#xD;
      protein levels within the first year after transplantation) in vitamin D deficient kidney&#xD;
      transplant recipients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Apart from its classical actions in calcium homeostasis, vitamin D acts as a potent&#xD;
      immunomodulatory agent. As such, vitamin D is thought to have beneficial effects in the&#xD;
      transplant setting, especially in kidney transplant recipients considering the fact that&#xD;
      approximately 40% of all kidney transplant recipients are vitamin D deficient.&#xD;
&#xD;
      Therefore, the objective is to conduct a randomized, double-blind, placebo-controlled study&#xD;
      focusing on the impact of Cholecalciferol substitution in vitamin D deficient kidney&#xD;
      transplant recipients on graft function (glomerular filtration rate as well as serum&#xD;
      creatinine levels), incidence of acute rejection episodes, frequency and severity (CRP&#xD;
      levels) of posttransplant infections within the first year after kidney transplantation.&#xD;
&#xD;
      Moreover, the impact of Vitamin D3 on renal osteodystrophy will be analyzed by means of bone&#xD;
      mineral density. DXA measurements will be performed during the first four weeks after kidney&#xD;
      transplantation, after 5, and after 12 months posttransplant.&#xD;
&#xD;
      Kidney transplant recipients found to have vitamin D deficiency (defined as 25-hydroxyvitamin&#xD;
      D &lt; 50 nmol/l) will be included and will be randomized to receive either oral Vitamin D3&#xD;
      therapy or placebo. Vitamin D3 will be administered at a daily dose of 6800IU over a time&#xD;
      period of one year.&#xD;
&#xD;
      All in all, 200 subjects will be included in the VITA-D study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The immunologic effects of Vitamin D3 substitution in vitamin D deficient kidney transplant recipients will be evaluated by means of: Glomerular filtration rate</measure>
    <time_frame>one year after kidney transplantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of acute rejection episodes</measure>
    <time_frame>one year after kidney transplantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of infections</measure>
    <time_frame>one year after kidney transplantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CRP levels</measure>
    <time_frame>one year after kidney transplantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Courses of calcium levels</measure>
    <time_frame>within the first year after kidney transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The impact of Vitamin D3 substitution on renal osteopathy will be analyzed by means of absolute bone mineral density (g/cm2)</measure>
    <time_frame>within the first year after kidney transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Kidney Transplantation</condition>
  <condition>Vitamin D Deficiency</condition>
  <condition>Renal Osteodystrophy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6800 IU/day of Cholecalciferol (Vitamin D3) orally for one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo solution daily for one year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>6800 IU of Cholecalciferol will be administered in the form of Oleovit® D3-drops once a day for one year. Treatment starts on day 5 after kidney transplantation. At serum calcium levels &gt;2,65 mmol/l vitamin D3 administration will be reduced to 3600 IU per day. If calcium levels persist above 2,85 mmol/l over a period of four weeks vitamin D3 administration will be discontinued and restarted when serum calcium levels declined to ≤ 2,65 mmol/l with only 3600 International Units per day.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Vitamin D3</other_name>
    <other_name>Oleovit® D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>An oral placebo solution matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for one year. Treatment starts on day 5 after kidney transplantation.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age &gt; 18&#xD;
&#xD;
          -  deceased donor kidney transplant recipients&#xD;
&#xD;
          -  only kidney transplant recipients&#xD;
&#xD;
          -  vitamin D deficiency defined as 25 (OH)D &lt; 50nmol/l&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  re-transplantation for the second time if the patient is highly immunized and&#xD;
             therefore included in the aphaeresis program&#xD;
&#xD;
          -  re-transplantation for the third or further time&#xD;
&#xD;
          -  significant impaired intestinal resorption: malabsorption due to celiac sprue,&#xD;
             systemic scleroderma; maldigestion due to chronic pancreatitis, pancreatic&#xD;
             insufficiency, pancreas resection, mucoviscidosis, Zollinger-Ellison-syndrome&#xD;
&#xD;
          -  history of inflammatory bowel disease: Crohn's disease, ulcerative colitis&#xD;
&#xD;
          -  previous gastrectomy, small bowel or large bowel resection, intestinal bypass surgery&#xD;
&#xD;
          -  severe liver disease: cirrhosis&#xD;
&#xD;
          -  HIV positive&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyra Borchhardt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna, Department of Internal Medicine III, Division of Nephrology and Dialysis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna, Department of Internal Medicine III, Division of Nephrology and Dialysis</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>September 11, 2008</study_first_submitted>
  <study_first_submitted_qc>September 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2008</study_first_posted>
  <last_update_submitted>January 20, 2014</last_update_submitted>
  <last_update_submitted_qc>January 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Kyra Borchhardt</investigator_full_name>
    <investigator_title>Priv.-Doz. Dr.</investigator_title>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Cholecalciferol</keyword>
  <keyword>Vitamin D3</keyword>
  <keyword>25-hydroxyvitamin D3</keyword>
  <keyword>Immunomodulation</keyword>
  <keyword>Vitamin D deficiency</keyword>
  <keyword>Kidney transplantation</keyword>
  <keyword>Renal transplantation</keyword>
  <keyword>Graft function</keyword>
  <keyword>Acute rejection</keyword>
  <keyword>Renal osteodystrophy</keyword>
  <keyword>Posttransplant bone loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Kidney Disease-Mineral and Bone Disorder</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

